Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

PZ0006

Sigma-Aldrich

Exemestan

≥98% (HPLC)

Synonym(e):

6-Methylenandrosta-1,4-dien-3,17-dion

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

5 MG
€ 130,00
25 MG
€ 507,00

€ 130,00

Check Cart for Availability
Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
5 MG
€ 130,00
25 MG
€ 507,00

About This Item

Empirische Formel (Hill-System):
C20H24O2
CAS-Nummer:
107868-30-4
Molekulargewicht:
296.40
MDL-Nummer:
MFCD00866994
UNSPSC-Code:
51111800
PubChem Substanz-ID:
329823675
NACRES:
NA.77

€ 130,00

Check Cart for Availability
Bulk-Bestellung anfordern

Assay

≥98% (HPLC)

Form

powder

Optische Aktivität

[α]/D +250 to +300°, c = 1 in methanol

Farbe

white to off-white

Löslichkeit

DMSO: ≥20 mg/mL

Lagertemp.

2-8°C

SMILES String

C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O

InChI

1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1

InChIKey

BFYIZQONLCFLEV-DAELLWKTSA-N

Angaben zum Gen

human ... CYP19A1(1588)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Biochem./physiol. Wirkung

Exemestane is a steroidal antiestrogen and irreversible aromatase inhibitor. Exemestane acts as a false substrate for the aromatase enzyme. Exemestane also prevents the conversion of androgens to estrogens and is used to treat estrogen-dependent breast cancer.
Exemestane is a steroidal antiestrogen; aromatase inhibitor.

Leistungsmerkmale und Vorteile

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Piktogramme

Health hazardEnvironment
GHS08,GHS09

Signalwort

Danger

H-Sätze

H360,H411

Gefahreneinstufungen

Aquatic Chronic 2 - Repr. 1B

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000362182
0000362182
037M4720V
100M4705

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 7

1 of 7

vibrant-m

Y0001522

Anastrozol

Fulvestrant >98% (HPLC)

Sigma-Aldrich

I4409

Fulvestrant

Fadrozole hydrochloride ≥98% (HPLC)

Sigma-Aldrich

F3806

Fadrozole hydrochloride

Everolimus ≥95% (HPLC)

Sigma-Aldrich

SML2282

Everolimus

Capecitabin ≥98% (HPLC)

Sigma-Aldrich

SML0653

Capecitabin

Letrozol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1540

Letrozol

Raloxifen -hydrochlorid solid

Sigma-Aldrich

R1402

Raloxifen -hydrochlorid

Michael Gnant et al.
Journal of the National Cancer Institute, 105(9), 654-663 (2013-02-22)
Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2), a phase III study in postmenopausal women with estrogen receptor-positive breast cancer progressing despite nonsteroidal aromatase inhibitor therapy, showed statistically significant benefits with adding everolimus to exemestane. Moreover, in preclinical studies, mammalian
Anneleen Lintermans et al.
Expert opinion on drug safety, 10(3), 473-487 (2011-03-25)
Hormone-dependent breast cancer can be successfully treated by either blocking the estrogen receptor, as with tamoxifen, or reducing the production of estrogens, as with aromatase inhibitors. Exemestane is a third-generation aromatase inhibitor used in the treatment of estrogen-receptor-positive breast cancer
Duveken B Y Fontein et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(18), 2257-2264 (2013-04-24)
Specific adverse events (AEs) associated with endocrine therapy and related to depletion or blocking of circulating estrogens may be related to treatment efficacy. We investigated the relationship between survival outcomes and specific AEs including vasomotor symptoms (VMSs), musculoskeletal adverse events
Elizabeth Maunsell et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(14), 1427-1436 (2014-04-09)
Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary
John M S Bartlett et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(36), 4477-4484 (2012-10-10)
Some postmenopausal patients with hormone-sensitive early breast cancer remain at high risk of relapse despite endocrine therapy and, in addition, might benefit from adjuvant chemotherapy. The challenge is to prospectively identify such patients. The Mammostrat test uses five immunohistochemical markers
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.